• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms.

作者信息

Procter A W, Francis P T, Stratmann G C, Bowen D M

机构信息

Miriam Marks Department of Neurochemistry, Institute of Neurology, London.

出版信息

Neurochem Res. 1992 Sep;17(9):917-22. doi: 10.1007/BF00993268.

DOI:10.1007/BF00993268
PMID:1357564
Abstract

Behavioural symptoms of Alzheimer's disease, such as aggression, may determine the care patients required. Most postmortem neurochemical studies have been of institutionalized patients and conclusions drawn from these may not be valid for all patients. We have shown that serotonin 2 receptors are not lost from 12 of the 13 areas of cerebral cortex examined in the patients assessed to be free of aggressive symptoms. This has been interpreted as representing the relative preservation of cortical interneurones. In contrast choline acetyltransferase activity was reduced in all areas whereas serotonin content was reduced in only 2 of the 4 areas examined.

摘要

相似文献

1
Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms.
Neurochem Res. 1992 Sep;17(9):917-22. doi: 10.1007/BF00993268.
2
Neurochemical characteristics of early and late onset types of Alzheimer's disease.早发型和晚发型阿尔茨海默病的神经化学特征
Br Med J (Clin Res Ed). 1984 Mar 31;288(6422):961-4. doi: 10.1136/bmj.288.6422.961.
3
Possible neurotransmitter basis of behavioral changes in Alzheimer's disease.阿尔茨海默病行为改变可能的神经递质基础。
Ann Neurol. 1988 Jun;23(6):616-20. doi: 10.1002/ana.410230616.
4
Topographical distribution of neurochemical changes in Alzheimer's disease.阿尔茨海默病中神经化学变化的地形分布。
J Neurol Sci. 1988 Apr;84(2-3):125-40. doi: 10.1016/0022-510x(88)90118-9.
5
A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease.
J Neurol Sci. 1988 Mar;84(1):101-16. doi: 10.1016/0022-510x(88)90179-7.
6
Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease.阿尔茨海默病两个阶段脑组织中的γ-氨基丁酸浓度。
Brain. 1988 Aug;111 ( Pt 4):785-99. doi: 10.1093/brain/111.4.785.
7
Human striatum: chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer's disease.人类纹状体:健康和阿尔茨海默病状态下尾状核、壳核及腹侧纹状体的化学结构
Neuroscience. 1994 Jun;60(3):621-36. doi: 10.1016/0306-4522(94)90491-x.
8
Postmortem studies of peptides in Alzheimer's disease and Huntington's disease.
Res Publ Assoc Res Nerv Ment Dis. 1986;64:259-77.
9
Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease.
Ann Neurol. 1990 Aug;28(2):157-61. doi: 10.1002/ana.410280207.
10
Neurotransmitters of the cerebral cortex in senile dementia of Alzheimer type.阿尔茨海默病型老年痴呆症中大脑皮质的神经递质
Exp Brain Res. 1982;Suppl 5:153-7. doi: 10.1007/978-3-642-68507-1_21.

引用本文的文献

1
Behavioral and Psychological Symptoms (BPSD) in Alzheimer's Disease (AD): Development and Treatment.阿尔茨海默病(AD)中的行为和心理症状(BPSD):发展与治疗
Curr Top Behav Neurosci. 2025;69:245-273. doi: 10.1007/7854_2024_566.
2
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.西酞普兰治疗阿尔茨海默病激越(S-CitAD):一项由研究者发起的、随机、对照、多中心临床试验的方法和设计。
Alzheimers Dement. 2019 Nov;15(11):1427-1436. doi: 10.1016/j.jalz.2019.06.4946. Epub 2019 Oct 3.
3
Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

本文引用的文献

1
Coexistence of cognitive impairment and depression in geriatric outpatients.老年门诊患者认知障碍与抑郁并存的情况。
Am J Psychiatry. 1982 May;139(5):623-6. doi: 10.1176/ajp.139.5.623.
2
Preliminary report on affective symptoms in the early stages of senile dementia of the Alzheimer type.
Am J Psychiatry. 1983 Feb;140(2):233-5. doi: 10.1176/ajp.140.2.233.
3
Reduced binding of [3H]ketanserin to cortical 5-ht2 receptors in senile dementia of the Alzheimer type.在阿尔茨海默型老年痴呆症中,[3H]酮色林与皮质5-羟色胺2受体的结合减少。
大麻素用于治疗阿尔茨海默病中的激越和攻击行为
CNS Drugs. 2015 Aug;29(8):615-23. doi: 10.1007/s40263-015-0270-y.
4
Citalopram for agitation in Alzheimer's disease: design and methods.西酞普兰治疗阿尔茨海默病激越:设计与方法。
Alzheimers Dement. 2012;8(2):121-30. doi: 10.1016/j.jalz.2011.01.007. Epub 2012 Feb 1.
5
Brain aging research at the close of the 20th century: from bench to bedside.20世纪末的脑衰老研究:从实验室到临床应用
Dialogues Clin Neurosci. 2001 Sep;3(3):167-80. doi: 10.31887/DCNS.2001.3.3/ccmeltzer.
6
Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.SSRIs 治疗阿尔茨海默病的潜在认知增强和疾病修饰作用。
Neuropsychiatr Dis Treat. 2007;3(5):627-36.
7
Disruptive behavior as a predictor in Alzheimer disease.破坏性行为作为阿尔茨海默病的一个预测指标
Arch Neurol. 2007 Dec;64(12):1755-61. doi: 10.1001/archneur.64.12.1755.
8
Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy.额颞叶痴呆中血清素能系统的失衡:对药物治疗的启示。
Psychopharmacology (Berl). 2008 Mar;196(4):603-10. doi: 10.1007/s00213-007-0992-8. Epub 2007 Nov 18.
9
Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients.阿尔茨海默病患者和正常衰老患者前额叶皮质中的血清素5-HT2A和5-HT6受体。
BMC Neurosci. 2006 Apr 27;7:36. doi: 10.1186/1471-2202-7-36.
10
Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease.死后颞叶皮质中5-羟色胺5-HT2A受体的丧失与阿尔茨海默病的认知衰退速率相关。
Psychopharmacology (Berl). 2005 May;179(3):673-7. doi: 10.1007/s00213-004-2077-2. Epub 2004 Nov 18.
Neurosci Lett. 1984 Jan 27;44(1):47-51. doi: 10.1016/0304-3940(84)90219-2.
4
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.阿尔茨海默病的临床诊断:美国国立神经疾病与中风研究所-阿尔茨海默病及相关疾病协会工作组在卫生与公众服务部阿尔茨海默病特别工作组主持下的报告。
Neurology. 1984 Jul;34(7):939-44. doi: 10.1212/wnl.34.7.939.
5
Cortical serotonin-S2 receptor binding abnormalities in patients with Alzheimer's disease: comparisons with Parkinson's disease.
Neurosci Lett. 1984 Oct 26;51(3):353-7. doi: 10.1016/0304-3940(84)90402-6.
6
A new rating scale for Alzheimer's disease.一种用于阿尔茨海默病的新评定量表。
Am J Psychiatry. 1984 Nov;141(11):1356-64. doi: 10.1176/ajp.141.11.1356.
7
Serotonin receptor changes in dementia of the Alzheimer type.阿尔茨海默型痴呆中的血清素受体变化
J Neurochem. 1984 Dec;43(6):1574-81. doi: 10.1111/j.1471-4159.1984.tb06081.x.
8
The psychiatric differentiation of senility and arteriosclerosis.衰老与动脉硬化的精神科鉴别
Br J Psychiatry. 1972 Mar;120(556):321-5. doi: 10.1192/bjp.120.556.321.
9
Alzheimer's disease.阿尔茨海默病
Arch Neurol. 1969 Jul;21(1):109-10. doi: 10.1001/archneur.1969.00480130123013.
10
Behavioral correlates of computed tomographic (CT) scan changes in older psychiatric patients.老年精神科患者计算机断层扫描(CT)变化的行为相关性。
J Am Geriatr Soc. 1985 Feb;33(2):96-103. doi: 10.1111/j.1532-5415.1985.tb02273.x.